Details of the Drug Combination

General Information of Drug Combination (ID: DCZGP55)

Drug Combination Name
CDX-1401 CDX-301
Indication
Disease Entry Status REF
Solid tumour/cancer Phase 1 [1]
Component Drugs CDX-1401   DMCGNJ6 CDX-301   DMKRFCO
N.A. N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CDX-1401
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
CDX-1401 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cancer/testis antigen 1 (NY-ESO-1) TTE5ITK CTG1B_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of CDX-301
Disease Entry ICD 11 Status REF
Hematopoietic stem cell transplantation QB63 Phase 2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Multiple myeloma 2A83 Phase 1 [2]
CDX-301 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02129075) CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma. U.S. National Institutes of Health.
4 National Cancer Institute Drug Dictionary (drug id 651880).
5 Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015 Jul;50(7):924-30.